Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775761 · ClinicalTrials.gov registry record · Phase 1
A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)
A Phase 1 study of TTR Cardiomyopathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT01775761: Completed Phase 1 study of TTR Cardiomyopathy, sponsored by Pfizer.
NCT01775761 is a Phase 1 study of TTR Cardiomyopathy that has completed, run by Pfizer. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775761, a Phase 1 study of TTR Cardiomyopathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.
Conditions Studied
Interventions
- DRUG Period 1
- DRUG Period 2
- DRUG Period 3
Study Locations (3)
Connecticut
- Pfizer Investigational Site - New Haven
Other
- Pfizer Investigational Site - Brussels
Singapore
- Pfizer Investigational Site - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
What the finished NCT01775761 record still lists
NCT01775761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with TTR Cardiomyopathy appearing as the primary indexed condition, and to 3 interventions - of which Period 1 is the first listed.
NCT01775761 reports a single indexed study location in Connecticut, Other, Singapore.
Frequently Asked Questions
What is clinical trial NCT01775761 about?
NCT01775761 is a clinical study titled "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)". The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.
What is the current status of trial NCT01775761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2013-01. Estimated completion is 2013-04.
What conditions does trial NCT01775761 study?
This clinical trial studies the following conditions: TTR Cardiomyopathy.
What interventions are being tested in trial NCT01775761?
The interventions under investigation include: Period 1 (DRUG), Period 2 (DRUG), Period 3 (DRUG).
Who is sponsoring clinical trial NCT01775761?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01775761 being conducted?
This trial has 3 study locations across Connecticut, Singapore. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01775761's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia